Situated in Foster City, California, Gilead Sciences, Inc. (GILD) is a top biopharmaceutical company specializing in the ...

(Reuters) - Gilead Sciences and the U.S. government have settled a billion ... respond to a request for comment and more ...

Fintel reports that on January 10, 2025, Morgan Stanley upgraded their outlook for Gilead Sciences (SNSE:GILD) from Equal-Weight to Overweight. There are 2,888 funds or institutions reporting ...

"Gilead Sciences, Inc. (NASDAQ:GILD), headquartered in Foster City, CA, is one of the world’s largest and best-managed research-based biopharmaceutical companies that discovers, develops ...

As the announcer told the crowd that it was Foster's '10th nomination and fifth win' Vergara was pictured rising up from her seat and approaching the stage as she exclaimed, 'Oh no, give me one!' ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $91.41, reflecting a -0.51% shift from the previouse trading day's closing. The stock's performance was behind the S&P ...

In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other dividend stocks. Macroeconomic factors have weighed on US stocks in the final ...

HPV-16 E7 is under clinical development by Gilead Sciences and currently in Phase II for Human ... Gilead is headquartered in Foster City, California, the US. For a complete picture of HPV-16 E7’s ...

Gilead's stock is rated a "buy" due to its thriving HIV business, promising oncology pipeline, and potential for long-term growth despite some volatility. The company's Q3 earnings show strong ...